CHOP / CEOP 化学療法プロトコル

使用用途

• Lymphoma (CHOP/CEOP Protocol - Vincristine)
• Lymphoma (CHOP/CEOP Protocol - Prednisolone)
• Lymphoma (CHOP/CEOP Protocol - Cyclophosphamide)
• Lymphoma (CHOP/CEOP Protocol - Furosemide)
• Lymphoma (CHOP/CEOP Protocol - Doxorubicin or Epirubicin)
• Lymphoma (CHOP/CEOP Protocol - Maropitant)
• Lymphoma (CHOP/CEOP Protocol - Omeprazole)
• Lymphoma (Alternative to Cyclophosphamide - Chlorambucil)
• Lymphoma (Alternative to Doxorubicin - Mitoxantrone)

投与方法

考えられる副作用

• Myelosuppression (neutropenia, thrombocytopenia)
• Gastrointestinal toxicity (vomiting, diarrhea, anorexia)
• Haemorrhagic cystitis (specific to cyclophosphamide)
• Severe tissue necrosis if extravasated (vincristine, doxorubicin)
• Cardiotoxicity (specific to doxorubicin)
• Alopecia (breed dependent)

注意事項と禁忌

• Severe myelosuppression (neutrophil count < 3 x 10^9/l)
• Pre-existing severe cardiac dysfunction (relative contraindication for doxorubicin; use mitoxantrone instead)
• Active haemorrhagic cystitis (substitute cyclophosphamide with chlorambucil)
• MDR1 mutation (requires significant dose reduction or avoidance of vincristine and doxorubicin)
• > **Myelosuppression Management:** * If neutrophils >3 x 10^9/l and platelets >100 x 10^9/l: Proceed with treatment. * If neutrophils <3 x 10^9/l: Suspend treatment, recheck in 5-7 days. * If neutrophils <1 x 10^9/l: Prescribe prophylactic antibiotics. Decrease next dose of the responsible chemotherapy drug by 10%. * If neutrophils <1 x 10^9/l AND patient is pyrexic/unwell: Administer IV antibiotics and contact an oncologist. > **MDR1 Breeds:** Collie-type breeds are highly sensitive to vincristine and doxorubicin due to the MDR1 (ABCB1) mutation. Commercial testing is strongly recommended prior to initiating therapy.

薬物相互作用

• Cimetidine: Alters hepatic cytochrome P450 enzyme pathway, potentially altering the metabolism and increasing toxicity of chemotherapeutics.

よくある質問